JP2018530581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530581A5 JP2018530581A5 JP2018519274A JP2018519274A JP2018530581A5 JP 2018530581 A5 JP2018530581 A5 JP 2018530581A5 JP 2018519274 A JP2018519274 A JP 2018519274A JP 2018519274 A JP2018519274 A JP 2018519274A JP 2018530581 A5 JP2018530581 A5 JP 2018530581A5
- Authority
- JP
- Japan
- Prior art keywords
- dmso
- soluble
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021164809A JP2022008902A (ja) | 2015-10-14 | 2021-10-06 | ベータ細胞の複製及び／または生存の亢進 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241566P | 2015-10-14 | 2015-10-14 | |
| US62/241,566 | 2015-10-14 | ||
| US201662279908P | 2016-01-18 | 2016-01-18 | |
| US62/279,908 | 2016-01-18 | ||
| PCT/US2016/056528 WO2017066240A1 (en) | 2015-10-14 | 2016-10-12 | Enhancing beta cell replication and/or survival |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164809A Division JP2022008902A (ja) | 2015-10-14 | 2021-10-06 | ベータ細胞の複製及び／または生存の亢進 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018530581A JP2018530581A (ja) | 2018-10-18 |
| JP2018530581A5 true JP2018530581A5 (enExample) | 2019-05-09 |
| JP6957455B2 JP6957455B2 (ja) | 2021-11-02 |
Family
ID=58518528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519274A Active JP6957455B2 (ja) | 2015-10-14 | 2016-10-12 | ベータ細胞の複製及び／または生存の亢進 |
| JP2021164809A Pending JP2022008902A (ja) | 2015-10-14 | 2021-10-06 | ベータ細胞の複製及び／または生存の亢進 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164809A Pending JP2022008902A (ja) | 2015-10-14 | 2021-10-06 | ベータ細胞の複製及び／または生存の亢進 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180235916A1 (enExample) |
| EP (1) | EP3362069A4 (enExample) |
| JP (2) | JP6957455B2 (enExample) |
| KR (1) | KR20180054796A (enExample) |
| CN (1) | CN108697712A (enExample) |
| AU (2) | AU2016338916B2 (enExample) |
| WO (1) | WO2017066240A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| AU2013352141B2 (en) | 2012-11-30 | 2018-04-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| KR20240157128A (ko) | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| US11992495B2 (en) | 2017-06-23 | 2024-05-28 | The Regents Of The University Of California | Enhancing GABA's ability to modulate immune responses |
| WO2020081885A1 (en) * | 2018-10-18 | 2020-04-23 | The Regents Of The University Of California | Combination therapies for treatment of inflammatory diseases |
| CN115361944A (zh) * | 2020-01-10 | 2022-11-18 | 均衡生物制药私人有限责任公司 | 用阿维菌素治疗神经病症 |
| US20250375429A1 (en) * | 2024-05-29 | 2025-12-11 | Smarter Not Harder, Inc. | Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350769B1 (en) * | 1999-02-24 | 2002-02-26 | The Regents Of The University Of California | Gaba alpha receptors mediate inhibition of T cell responses |
| DK2621282T3 (da) * | 2010-09-28 | 2020-05-04 | Univ California | Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes |
| ES2666465T3 (es) * | 2012-09-27 | 2018-05-04 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Métodos para producir una población de células beta pancreáticas |
| AU2015233686B2 (en) * | 2014-03-18 | 2019-07-11 | Algiax Pharmaceuticals Gmbh | 2-Cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives |
-
2016
- 2016-10-12 JP JP2018519274A patent/JP6957455B2/ja active Active
- 2016-10-12 KR KR1020187011125A patent/KR20180054796A/ko not_active Ceased
- 2016-10-12 AU AU2016338916A patent/AU2016338916B2/en active Active
- 2016-10-12 WO PCT/US2016/056528 patent/WO2017066240A1/en not_active Ceased
- 2016-10-12 CN CN201680060060.XA patent/CN108697712A/zh active Pending
- 2016-10-12 EP EP16856063.9A patent/EP3362069A4/en not_active Withdrawn
- 2016-10-12 US US15/761,795 patent/US20180235916A1/en not_active Abandoned
-
2021
- 2021-10-06 JP JP2021164809A patent/JP2022008902A/ja active Pending
-
2022
- 2022-03-23 AU AU2022202004A patent/AU2022202004B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530581A5 (enExample) | ||
| NL301260I2 (nl) | Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout. | |
| JP2017514877A5 (enExample) | ||
| JP2014237817A5 (enExample) | ||
| JP2016196495A5 (enExample) | ||
| JP2016028081A5 (enExample) | ||
| DK3297637T3 (da) | Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf | |
| JP2017519346A5 (enExample) | ||
| JP2016503708A5 (enExample) | ||
| SG11201801534RA (en) | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | |
| DK3612579T3 (da) | Pultrudat, fremstilling og anvendelse heraf | |
| MX2017006953A (es) | Medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| JP2015173751A5 (enExample) | ||
| JP2017149782A5 (enExample) | ||
| HUE070649T2 (hu) | Benzimidazol-származékok és felhasználásuk | |
| TWI561508B (en) | Onium salt, chemically amplified positive resist composition, and patterning process | |
| JP2016540019A5 (enExample) | ||
| HUE049374T2 (hu) | 3-(karboxietil)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-dekán származékok | |
| LT3402785T (lt) | 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai | |
| JP2015016294A5 (enExample) | ||
| DK3604303T3 (da) | Hidtil ukendt pyrrolopyridinderivat, fremgangsmåde til fremstilling heraf og anvendelse deraf | |
| JP2017528459A5 (enExample) | ||
| JP2017197541A5 (enExample) | ||
| JP2018519528A5 (enExample) | ||
| JP2020086730A5 (enExample) |